Executive Summary
ARGX-124 is an FcRn-targeting molecule in Phase 1, part of argenx's strategy to build a diversified FcRn franchise with 3 clinical-stage molecules.
ARGX-124
FcRn · FcRn-targeting molecule
Mechanism of Action
Target Biology[Corp '26 S16]
Third FcRn molecule in argenx portfolio after efgartigimod and ARGX-213, contributing to enduring FcRn leadership strategy.
Clinical Data
No clinical trial data available.
Market Opportunity
Catalysts & Upcoming Events
No catalyst data available.